Efficacy of Andrographis paniculata, Nees for pharyngotonsillitis in adults.

One hundred and fifty-two adult patients with pharyngotonsillitis were enrolled in the randomized double blind study to assess the efficacy of Andrographis paniculata. The patients were randomized to receive either paracetamol or 3 g/day of Andrographis paniculata or 6 g/day of Andrographis paniculata for 7 days. The baseline characteristics of the patients among the three groups were not different. The efficacy of paracetamol or high dose Andrographis paniculata was significantly more than that of low dose Andrographis paniculata at day 3 in terms of the relief of fever and sore throat. The clinical effects were not different at day 7. Minimal and self limiting side effects were found in about 20 per cent in each group.

Randomized controlled trial of Cassia alata Linn. for constipation.

Cassia alata Linn. is a medical plant. Its leaves have been claimed to be effective as a laxative. The studies done so far have shown no toxicity as a result of consuming Cassia alata Linn. leaves. The plant has been found to contain anthraquinones, presumed to be the active ingredient causing the laxative effect. The objective of the study was to test efficacy of Cassia alata Linn. leaves for treatment of constipation compared with a placebo and mist. alba in a multicenter randomized controlled trial carried out in one provincial and 5 community hospitals. Eighty adult patients admitted to 5 community hospitals and one provincial hospital with at least 72 hours of constipation were included in the study. Twenty-eight patients were in the placebo group, 28 in the mist. alba group, and 24 in Cassia alata Linn. group. Each patient was given 120 ml of fluid with caramel color, mist. alba, or Cassia alata Linn. infusion at bed time. Evaluation was performed after 24 hours whether the patient defecated or not. The characteristics of the patients among the three groups were not different. Eighteen per cent of patients in the placebo group passed stools within 24 hours, whereas, 86 and 83 per cent of patients in mist. alba and Cassia alata Linn. groups respectively, passed stools. The differences observed between placebo and mist. alba, placebo and Cassia alata Linn. were statistically highly significant, P less than 0.001 and clinically important. Minimal self-limited side effects, i.e., nausea, dyspepsia, abdominal pain and diarrhea were noted in 16-25 per cent of the patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Randomized double blind study of Curcuma domestica Val. for dyspepsia.

Curcuma domestica Val. is a medicinal plant. It has been claimed to be effective for dyspepsia. The studies done so far showed no toxicity due to consuming Curcuma domestica Val. The plant has been found to contain volatile oil and curcuminoids which are believed to be the active ingredients. The objective of the study was to test the efficacy of Curcuma domestica Val. rhizome for treatment of dyspepsia compared with a placebo and flatulence in a multicenter, randomized, double-blind trial carried out in one provincial and 5 community hospitals. One hundred and sixteen adult patients who had acid dyspepsia, flatulent dyspepsia, or atonic dyspepsia were included in the study. Forty-one (41) patients were in the placebo group, 36 and 39 were in the flatulence and Curcuma domestica Val. groups respectively. Each patient received 2 capsules of placebo or study drugs 4 times a day for 7 days. Each patient was then assessed for symptoms response, side effects and satisfaction. Ten patients did not participate in the follow-up. The baseline characteristics of the patients among the three groups were not significantly different. Fifty-three (53) per cent of the patients receiving placebo responded to the treatment whereas 83 per cent of the patients receiving flatulence and 87 per cent of patients receiving Curcuma domestica Val. responded to the treatment. The differences in efficacy between placebo and active drugs were statistically significant and clinically important. Mild and self-limited side effects were observed at similar frequency in the three groups. About 50 per cent of the patients in each group were satisfied with the treatment they received.(ABSTRACT TRUNCATED AT 250 WORDS)

Clinical assessment of the efficacy and tolerance of zingiber cassumunar roxb in bronchial asthma.

An open study was carried out on 22 individuals with a moderate degree of assess the prophylactic efficacy and tolerance of Zingiber cassumunar Roxb. The group consisted of 8 men and 16 women, aged 19-64 years (mean age 44.1 years). After six weeks of basal assessment, all subjects received oral Zingiber cassumunar Roxb, at a dosage of 500 mg. per day for body weight of 50 kg. or under, 750 mg. per day for body weight between 50-55 kg. and 1,000 mg. if over 55 kg. The drug was given orally twice daily for 16 weeks. Examination of the patients was made before starting the treatment and after on the 2nd, 4th, 6th, 10th, 14th, 18th, 22nd week, respectively. Monitoring of the following parameters was performed: patient’s symptoms, ventilatory function, and consumption of antiasthmatic drugs. Zingiber cassumunar Roxb, was found to provide a significant protection against asthmatic attacks in 19 out of 22 cases (86.4%). Statistically significant reduction in asthmatic symptoms as well as the reduction in the use of bronchodilators and steroids were noted between 1-3 and 2-4 months after treatment respectively. Statistically significant improvement in peak expiratory flow rate and FEV1 were also noted in the second month of treatment. Slightly increased frequency in bowel movement was noted in 5 patients and one patient complained of mild headache.